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Fighting Fire with Fire in Cancer
Thorsten Berger, Mary E. Saunders, and Tak W. Mak
Abstract Cancer will not be cured until we understand and target the unique altera-
tions that distinguish tumor cells from normal cells. This chapter briefly describes 
four new approaches to anticancer therapy based on boosting the immune system’s 
response to tumor cells, countering the metabolic adaptations that allow tumor cells 
to thrive under conditions that kill normal cells, manipulating the increased oxida-
tive stress associated with the tumor environment, and exploiting the aneuploidy 
characteristic of many advanced tumor cells. The long-term goal is to devise bio-
markers and novel therapeutic agents able to more effectively fight aggressive 
cancers.
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 Introduction
Why has it been so difficult to cure cancer? The answer lies in our inability to define 
all of the elements that contribute to the transformation and survival of tumor cells, 
and challenges in dissecting the body’s responses to these malignant growths. As far 
back as 1924, Otto Warburg proposed that “The cause of cancer is the replacement 
of the respiration of oxygen in normal body cells by a fermentation of sugar,” a 
concept now widely known as the “Warburg effect” [1, 2]. Because this change 
would not alter the “antigenic face” of a cancer cell, the immune system would not 
be able to recognize these aberrant cells and remove them, necessitating externally 
imposed therapies. Oncologists of the day therefore focused on eliminating all fast-
replicating cells, normal or cancerous, by radiation or chemotherapy, a trend that 
remained firmly in place into the 1990s (Table 1).
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In a talk at a 1966 Nobel Laureates’ meeting, Warburg reiterated his belief that 
cancer cells ultimately arise when a switch from normal respiration to fermentation 
is caused by (for example) damage to the enzymatic machinery required for respira-
tion (see http://www.mediatheque.lindau-nobel.org/videos/31517/on-the-primary- 
causes-and-on-the-secondary-causes-of-cancer-german-presentation-1966/
laureate-warburg). However, in the 1970s, Warburg’s hypothesis was again side-
lined as scientists became convinced that the underlying cause of cancer was aber-
rant function of either oncogenes or tumor suppressor genes. After the discovery of 
Src in 1976 [3], a multitude of other oncogenes were identified, including EGFR, 
Her2, Abl, Raf, Alk, Btk, PI3’K, Tor, and many others. This focus on a genetic ori-
gin for cancer initiation was then reflected in the development of anticancer thera-
peutics. Since 1998, numerous therapeutic agents targeting specific oncogenes or 
other relevant molecules or structures have been approved (Table 2).
Although anti-oncogene agents have proven undeniably helpful, it has unfortu-
nately become clear that the cancer cell genome is too varied and oncogenes are too 
numerous for these strategies to be able to eradicate all tumors. As Robert Weinberg 
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said, “There are more paths to developing tumors than there are stars in the sky.” 
Pathways now known to be deregulated in cancer include the Hedgehog, Wnt/
Notch, TGFβR, FAS, and VEGFR pathways, as well as those involving receptor 
tyrosine kinases [4, 5]. Concomitantly, the development of new chemotherapeutics 
has slowed down significantly, with no new agent being approved in the last 10 
years. Researchers have instead returned to Warburg’s hypothesis and are exploring 
ways of disrupting tumor cell metabolism and mitosis, as well as seeking means of 
boosting anticancer immune responses. The long-term goal is to develop novel anti-
cancer therapeutics that differ from existing classes of agents and so may be more 
effective. In the following sections, we will describe our work on four novel avenues 
that show promise as future anticancer strategies: (1) boosting the immune system; 
(2) targeting cancer cell metabolism; (3) targeting reactive oxygen species; and 
(4) exploiting cancer cell aneuploidy.
 Boosting the Immune System
The objective of immunotherapy is to strengthen the body’s ability to recognize and 
attack tumor cells—that is, fight the fire of cancer with the fire of an aggressive 
immune response. Activation of the T lymphocytes that underpin any adaptive 
immune response requires two stimuli: (1) binding of the T cell receptor to a com-
plex of antigenic peptide plus MHC (pMHC), which delivers an antigen-specific 
signal; and (2) binding of CD28, a receptor expressed on the T cell surface, to CD80 
or CD86 ligands expressed on the surface of antigen-presenting cells (APCs), which 
delivers a co-stimulatory signal. In 1995, our group reported that T cell activation is 
negatively regulated by cytotoxic T lymphocyte antigen-4 (CTLA-4) in a manner 
vital for the control of lymphocyte homeostasis [6]. Subsequent work demonstrated 
that CTLA-4 exerts its inhibitory activity by binding to CD80 or CD86, thereby 
preventing the binding of CD28 to these surface proteins and blocking the co- 
stimulation needed for optimal T cell activation [7]. Several other negative regula-
tors of T cell activation, including PD1, have since been discovered [8, 9].
There are multiple reasons why the immune system is often unable to completely 
eradicate a cancer without help from targeted therapeutics. First, there are very few 
truly tumor-specific antigens, since healthy and malignant tissues are identical in 
most of their components. Second, the negative homeostatic regulation imposed by 
CTLA-4 and PD1 decreases the activation of antitumor T cells. Third, like chronic 
viral infections, cancers often induce T cell exhaustion, in which hyperactivated T 
cell clones display specific profiles of transcription factor and inhibitory receptor 
expression that eventually suppress the antitumor response [10]. Fourth, the general 
lack of co-stimulation characteristic of malignant tissue prevents the activation of 
antitumor T cells [11]. Fifth, cancers impede the homing of naïve T lymphocytes 
into tumor-draining lymph nodes, decreasing the probability of the rare interaction 
between T cells and APCs displaying the relevant pMHC complex [12]. This pleth-
ora of difficulties indicates that strengthening the antitumor response in vivo will 
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require a battery of complementary approaches. Accordingly, immunotherapies 
used to treat cancer patients have been devised that are antibody based, cytokine 
based, or cell based. In the following sections, we discuss some exciting results 
based on the first two approaches.
 Targeting CTLA-4
Because CTLA-4 is a negative regulator of T cell activation, agents have been 
designed to block CTLA-4 and thereby hopefully sustain antitumor T cell responses. 
In a phase 3 study of a human anti-CTLA-4 antibody (ipilimumab), a cohort of 
melanoma patients treated with this agent gained a significant survival advantage 
[13]. Suppression of the inhibitory signals generated by CTLA-4 apparently allowed 
prolonged activation of antitumor T cells. The success of this trial has led to renewed 
efforts to determine why antitumor CD8+ T cells do not routinely attack and kill 
cancer cells on their own, and how their activities can be boosted.
 IL-7 Treatment
Several groups have attempted to strengthen antitumor T cell responses in vivo by 
vaccination with tumor antigens, but clinical trials of this approach have not shown 
the expected efficacy [14]. In searching for ways to improve this result, our group 
discovered that vaccine-induced immune responses to tumors could be augmented 
and sustained by providing exogenous IL-7 [15]. In this study, we employed the 
RIP-TAG2 transgenic mouse model, in which mice expressing the SV40 large T 
antigen (TAG) under the control of the rat insulin promoter (RIP) develop pancre-
atic β-islet cell tumors [16]. We crossed these mice with transgenic mice expressing 
the lymphocytic choriomeningitis virus (LCMV) glycoprotein (GP) under the con-
trol of RIP [17] to produce RIP(GP x TAG2) mice. Tumors arising in these mice 
were not cleared by the immune system even though they expressed the foreign GP 
antigen [18]. Even after LCMV infection, which mimics administration of a live 
antitumor vaccine, only a limited increase in overall mouse survival occurred and no 
sustained antitumor response was observed [18]. However, if IL-7 treatment of 
LCMV-vaccinated tumor-bearing RIP(GP x TAG2) mice was initiated at 8 days 
after LCMV infection—a point that coincides with the peak of the CD8+ T cell 
response—the virus was eliminated, and mouse survival was prolonged by over 100 
days [11, 15].
Subsequent work focused on determining how IL-7 can overcome immune 
inhibitory networks during a chronic viral infection, which mimics the continuous 
production of a tumor antigen by a cancer [19]. Although IL-7 treatment had already 
shown significant therapeutic promise [20–22], and had been successfully used in 
several nonhuman primate SIV infection models [23–25], the efficacy of IL-7 in 
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promoting viral clearance had not been fully explored [19]. We administered IL-7 
to mice infected with LCMV clone 13, which establishes a chronic infection and 
generates massive viral antigen levels [26]. In part by enhancing thymic output, 
IL-7 treatment of LCMV-13-infected mice increased both the magnitude of the 
immune response and the size of the entire naive T cell pool, including T cell clones 
directed against non-LCMV epitopes [19]. LCMV-13-specific CD8+ T cells showed 
enhanced degranulation kinetics and cytokine production upon IL-7 exposure, 
resulting in PD-1 downregulation on effector T cells and efficient viral clearance 
[19]. IL-7 treatment also induced a cytokine milieu favoring leukocyte activation 
and production of the cytoprotective cytokine IL-22 [19]. At the molecular level, 
IL-7 led to a reduction in Socs3 expression in T cells that was FoxO dependent [19]. 
These model system data indicate that a combination of IL-7 and a cancer vaccine 
may result in an antitumor response capable of benefitting cancer patients.
 Targeting Cancer Cell Metabolism
“Oncogene addiction” is a concept devised to explain the observation that the inhi-
bition of crucial oncogenes, or the reconstitution of previously lost or repressed 
tumor suppressor genes, can have a broad antitumorigenic effect. However, in addi-
tion to their genetic and epigenetic alterations, cells undergoing transformation 
implement specific metabolic adaptations that are induced by their altered microen-
vironment. These adaptations lead to upregulation of the stress response and other 
pathways that are not inherently tumorigenic but allow developing tumor cells to 
survive under conditions that would kill normal cells [27]. This “metabolic addic-
tion” of pre-cancerous and ultimately cancerous cells provides new opportunities 
for specific therapeutic intervention, since normal cells, which have not had to 
endure the same constant internal and external stress, should be unaffected by 
agents targeting cancer cell metabolic adaptations.
 Targeting Carnitine Palmitoyltransferase-1C
Our group has discovered that carnitine palmitoyltransferase-1C (CPT1C), a brain- 
specific metabolic enzyme, may be involved in tumor cell metabolic adaptation to 
heightened environmental stress [28]. Expression of CPT1C, but not the ubiquitous 
CPT1A or heart-specific CPT1B, correlated inversely with mTOR pathway activa-
tion in tumor cells, indicating that CPT1C may act in a pathway parallel to mTOR- 
enhanced glycolysis [28, 29]. CPT1C contributes to rapamycin resistance in murine 
primary tumors and is overexpressed in human non-small-cell lung carcinomas 
(NSCLC) [28]. CPT1C overexpression in a human cancer cell line led to increased 
fatty acid oxidation and ATP production, and resistance to glucose deprivation or 
hypoxia [28]. Importantly, siRNA-mediated depletion of CPT1C reduced tumor 
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growth in an in vivo xenograft mouse model [28], and delayed tumor development 
and increased mouse survival in a neurofibromatosis type I tumor model [30–32]. 
Subsequent studies have established that CPT1C is a p53 target gene, and that 
CPT1C expression is induced by metabolic stress factors such as hypoxia and glu-
cose deprivation in a p53- and AMPK-dependent manner [32]. These results indi-
cate that p53 initially protects cells from metabolic stress via induction of CPT1C 
but that excessive CPT1C expression can promote carcinogenesis [32]. Because 
CPT1C expression is normally restricted to the brain, and most drugs cannot pene-
trate the blood–brain barrier, CPT1C may be an ideal candidate for specific small- 
molecule inhibition as a treatment for hypoxic and otherwise treatment-resistant 
cancers [29, 32].
 Targeting Mutated Isocitrate Dehydrogenases
Isocitrate dehydrogenase (IDH)-1 and IDH2 are metabolic enzymes that govern the 
important NADP/NADPH ratio in the cytoplasm and mitochondria, respectively. 
Oncogenic mutations to these enzymes have recently garnered much interest since 
their discovery during cancer genome sequencing projects [33–35]. The normal 
function of IDH1/2 is to convert isocitrate to α-ketoglutarate (αKG) while reducing 
NADP to NADPH and liberating CO2 [36]. To date, mutations of IDH1 altering a 
single arginine residue (R132) in the enzymatic active site have been found at high 
frequency in glioblastoma multiforme (GBM) [34], acute myeloid leukemia (AML) 
[33], cholangiocarcinoma [37, 38], and chondrosarcoma [39]. IDH1 R132 muta-
tions occur less frequently in other types of cancers such as melanoma, NSCLC, and 
prostate and colon cancers [40]. IDH2 mutations, predominantly R172K and R140Q 
[36, 41], have been identified in cholangiocarcinoma [37, 38], myelodysplastic syn-
drome (MDS) and myeloproliferative disorder (MPD) [42–44], AML [33], chon-
drosarcoma [39], angioimmunoblastic T cell lymphoma (AITL) [45], and D2HG 
aciduria [46].
In 2009, scientists at Agios Pharmaceuticals used a metabolite profiling strategy 
to make the breakthrough discovery that the tumorigenic effect of IDH1/2 muta-
tions is not due to a loss of function of these proteins. Instead, the mutant IDH 
enzymes acquire a neomorphic activity in which the normal product αKG is con-
verted to 2-hydroxyglutarate (D2HG) in a reaction that consumes, rather than pro-
duces, NADPH [36, 47].
To examine the pathophysiological consequences of IDH mutations in the most 
relevant in vivo system possible, our group generated a conditional knock-in mouse 
model using the lox-stop-lox (LSL) system. In the absence of Cre recombinase 
(Cre), neither the LSL IDH1 R132 mutant allele nor the wild type IDH allele is 
expressed, but when Cre is present, a stop codon is excised and the mutant IDH1 
protein is expressed from the endogenous locus [48]. Initial characterization of vari-
ous mouse strains revealed that IDH1 knockout mice were viable and fertile but that 
expression of the mutant IDH1 enzyme and its consequent D2HG production were 
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embryonic lethal [36]. Mutant IDH1 enzyme expressed solely in the myeloid com-
partment (LysM promoter) resulted in splenomegaly, decreased bone marrow cel-
lularity, and extramedullary hematopoiesis by age 6 months [48]. LysM IDH1 
knock-in LSK cells showed an increase in highly methylated CpG sites and histone 
hypermethylation [48], consistent with the DNA methylation changes observed in 
human IDH1- or IDH2-mutant gliomas [49] and AML [50].
The available data indicate that mutant IDH enzymes exert their tumor- promoting 
function through their novel enzymatic activity, which generates massive quantities 
of D2HG. Mechanistic studies of D2HG have focused on its competitive inhibition 
of 2-OG-dependent dioxygenases (2OGD), which use αKG as a cosubstrate [36]. In 
mammalian cells, there are more than 60 2OGD involved in collagen biosynthesis, 
fatty acid metabolism, DNA repair, RNA and chromatin modifications, and hypoxia 
detection [51]. The general enzymatic reaction performed by 2OGD converts αKG 
to succinate and CO2, and requires oxygen, ascorbate, and iron as cofactors [51]. 
D2HG has been shown in vitro to competitively inhibit 2OGD [52], and the high 
concentration of D2HG measured in cells and tissues of IDH-mutant tumors makes 
it very likely that D2HG impairs the activity of this class of enzymes in vivo as well 
[36]. Additional potential targets of D2HG inhibition include the TET proteins 
involved in DNA methylation, the JumonjiC domain-containing histone demethyl-
ases, the prolyl hydroxylases (PHD) and lysyl hydroxylases (LHD) required for 
collagen folding and maturation, and the PHDs that regulate hypoxia-inducible fac-
tor (HIF) signaling [36].
In early 2014, an oral, potent, reversible, and selective inhibitor (AG-221) of the 
mutated IDH2 protein underwent evaluation in a clinical trial of patients with 
advanced IDH2-mutant hematologic malignancies. Encouragingly, AG-221 treat-
ment reduced D2HG levels and demonstrated a dose-dependent survival benefit 
[53]. Pursuit of a similar compound to combat IDH1-mutant cancers is ongoing.
 Targeting Reactive Oxygen Species
An important cellular stress factor increased in cancer cells is the level of reactive 
oxygen species (ROS). ROS regulation is critical for normal cellular functions and 
survival, and the accelerated growth of tumor cells generates increased ROS. Cancers 
therefore need to adjust signaling pathways linked to ROS regulation to cope with 
their enhanced ROS. Elevated ROS are generated by hypoxia, defective metabo-
lism, endoplasmic reticulum (ER) stress, and oncogene activity [54]. Conversely, 
ROS are eliminated routinely via NADPH, glutathione, and dietary antioxidants, 
and under stress conditions through the activation of transcription factors such as 
NRF2 and the activity of tumor suppressors such as BRCA1, p53, PTEN, and ATM 
[54]. During carcinogenic progression from normal tissue to neoplastic transforma-
tion to carcinoma in situ and finally to invasive carcinoma, cellular ROS levels pro-
gressively increase because of metabolic aberrations acquired following 
transformation. Unlike normal cells, cancer cells can cope with this inexorable rise 
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in ROS by upregulating the above antioxidant pathways and transiently lowering 
ROS levels. Targeted therapeutics that interfere with this upregulation may there-
fore result in ROS increasing to the point where the apoptotic death of the cancer 
cell is induced. Alternatively, agents that increase ROS production beyond the 
capacity of the upregulated antioxidant mechanisms to cope may kill the tumor cell 
while sparing normal cells in which these pathways are not activated.
We recently explored whether altered ROS regulation could explain the tissue 
specificity of BRCA1-related cancers, which occur almost exclusively in the breast 
and ovary. We found that BRCA1 deficiency enhanced ROS levels in breast cancer 
cells and that Nrf2-driven antioxidant pathways were defective [55]. Further analy-
sis revealed that BRCA1 directly interacts with Nrf2 and that this interaction affects 
Keap1-mediated Nrf2 ubiquitination, stability, and activation [55]. Interestingly, 
estrogen treatment partially restored Nrf2 levels and enhanced tumor growth in the 
absence of BRCA1 [55, 56]. We hypothesize that loss of BRCA1 in heterozygous 
carriers of somatic BRCA1 mutations has different effects depending on the tissue. 
In tissues without an estrogen-rich environment, BRCA1 deficiency impairs Nrf2 
antioxidant signaling, leading to an accumulation of ROS in the BRCA1-deficient 
cells that kills them. However, in the breast and ovary, estrogen activates Nrf2 via a 
mechanism that depends on PI3K–AKT and protects BRCA1-deficient cells from 
ROS-induced death. If a BRCA1-deficient breast or ovarian cell also loses PTEN 
function, the PI3K–AKT pathway may be further stimulated and may reinforce 
estrogen-mediated Nrf2 signaling. Mitogenic and antioxidant pathways acting 
downstream of AKT, coupled with the genomic instability caused by a lack of 
BRCA1-mediated DNA repair, might then eventually drive the complete malignant 
transformation of the BRCA1-deficient cells [56]. Exploitation of the altered ROS 
regulation in these cells may serve as the basis for an effective therapy in the future.
 Exploiting Cancer Cell Aneuploidy
A long-term goal of our laboratory is to develop novel anticancer therapeutics that 
differ from existing classes of agents. We have recently taken advantage of an alter-
ation shared by many advanced cancer cells but not found in normal cells: 
aneuploidy.
By using a systematic approach that combines RNAi screening with gene expres-
sion analysis in human breast cancers and cell lines and focusing on cancer cell 
aneuploidy, we have identified polo-like kinase-4 (PLK4), an enzyme critical for 
aneuploidy maintenance, as a promising therapeutic target [57]. A drug discovery 
program culminated in the isolation of CFI-400945, a potent and selective small- 
molecule PLK4 inhibitor [57]. In vitro treatment of human cancer cells with CFI- 
400945 results in effects similar to those of siRNA-mediated PLK4 kinase inhibition, 
including mitotic defects, centriole duplication, and cell death [57]. In in vivo mouse 
models based on human ovarian or breast cancer xenografts, tumor growth was 
significantly inhibited by CFI-400945 in a manner influenced by the PTEN status of 
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the tumor [57]. PTEN-deficient xenografts showed a greater response to CFI- 
400945 than xenografts expressing wild type PTEN, making PTEN status a poten-
tial predictive biomarker for therapy with this first-in-class agent [57].
 Conclusion
This chapter has briefly outlined four innovative anticancer approaches under inves-
tigation in our laboratory. Our belief is that by concentrating on unique aspects of 
tumor biology, we can identify strategies and targets that are applicable to a broad 
range of cancers and less likely to induce damaging side-effects in normal tissues. 
By fighting the fire of malignancy with the fire of creative thinking, we hope to 
indeed conquer cancer in our lifetime.
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